Lakewood-Amedex Biotherapeutics, Inc.
LABT
$3.14
-$0.34-9.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -71.11% | 12.83% | 1.49% | 38.16% | 46.26% |
| Total Depreciation and Amortization | 2.69% | 2.71% | 1.69% | 0.67% | -0.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.13% | -23.69% | 1,961.82% | 254.35% | 163.73% |
| Change in Net Operating Assets | 853.74% | 860.55% | 132.04% | 29.19% | 105.09% |
| Cash from Operations | 13.46% | 42.83% | 70.16% | 47.24% | 79.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -37.50% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -37.50% | -- | 100.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.09% | -510.51% | 66.29% | -33.34% | 84.64% |